Clinical trials: Rifampin, active
Sepsis, Tuberculosis
STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis
Sepsis, a life-threatening condition due to a dysregulated response to infection, is the leading cause of global mortality and is frequently driven by tuberculosis (TB) and drug-resistant bacteria in sub-Saharan Africa…
- Trial name
- STARS (NCT07332325)
- Testing
- Hydrocortisone administration, Expanded antimicrobial therapy
- Where
- 4 sites in Tanzania, Uganda
- Volunteers
- 344 people
- Sponsor
- University of Virginia
Refractory or Relapsed Solid Tumors
Phase I Study of QLC5508 in Advanced Solid Tumors: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction
A clinical trial of QLC5508 for advanced solid tumors The goal of this clinical trial is to learn if QLC5508 can be given safely to adults with advanced solid tumors.
- Trial name
- NCT07620041
- Testing
- QLC5508 (Investigational Product / Formulation T), QLC5508 (Reference Product / Formulation R), Itraconazole
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Tuberculosis, Pulmonary
Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB
This study is being done to test an experimental study vaccine compared to a placebo. The experimental study vaccine is called ID93 + GLA-SE.
- Trial name
- NCT06205589
- Testing
- ID93 + GLA-SE vaccine
- Volunteers
- 1,500 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Adjuvant, Treatment
Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis
This study is designed to further strengthen the clinical application evidence of BaidiZiyin Pill and ShenqiYifei Pill in the treatment of tuberculosis.
- Conditions
- Adjuvant, Treatment, Tuberculosis
- Trial name
- NCT06403943
- Testing
- BaiDiZiYin Pill, ShenQiYiFei Pill, Anti tuberculosis chemotherapy
- Where
- China
- Volunteers
- 292 people
- Sponsor
- Beijing Chest Hospital
Tuberculosis
Re-evaluating the Duration in Children of TB Treatment
Current tuberculosis (TB) treatment is effective (works well), but it takes a long time to cure TB. This study will evaluate if TB treatment with a higher dose of rifampicin, one of the TB medicines, and shorter TB treatment…
- Trial name
- REDUCE TB (NCT07656012)
- Testing
- Rifampicin, Isoniazid, Pyrazinamide
- Where
- Peru
- Volunteers
- 230 people
- Sponsor
- University of Wisconsin, Madison
Prosthetic-joint Infection, Infection Hip
Rifampicin Combination Therapy Versus Monotherapy for Staphylococcal Prosthetic Joint Infection
In this Dutch multicenter clinical trial, patients with a staphylococcal prosthetic joint infection, will, in the oral antibiotic treatment phase, be randomized between clindamycin monotherapy and rifampicin / levofloxacin…
- Conditions
- Prosthetic-joint Infection, Infection Hip, Infection; Knee, Joint
- Trial name
- RiCOTTA (NCT06172010)
- Testing
- Clindamycin, Rifampicin and levofloxacin
- Where
- 13 sites in Netherlands
- Volunteers
- 316 people
- Sponsor
- Leiden University Medical Center
Tuberculosis, Acute Coronary Syndrome
Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis
Tuberculosis (TB) is a global pandemic that despite successful treatment and bacterial eradication can cause chronic ill health, such as pulmonary impairment after tuberculosis (PIAT) and cardiovascular disease (CVD).
- Conditions
- Tuberculosis, Acute Coronary Syndrome, Pulmonary Hypertension (Diagnosis)
- Trial name
- Doxy-TB (NCT05473520)
- Testing
- Doxycycline
- Where
- 6 sites in Malaysia, Singapore
- Volunteers
- 150 people
- Sponsor
- National University Hospital, Singapore
Healthy Adult Participants
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose trial of TBD11 in healthy adults. It includes a dedicated open-label cohort in which TBD11 will be administered as a single dose with either a strong…
- Trial name
- NCT07883226
- Testing
- TBD11 (300 mg), Itraconazole (200 mg), Rifampicin 600mg
- Where
- South Africa
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Drug Resistant Tuberculosis
Bring BPaL2Me Trial Comparing Nurse-Led RR-TB Treatment to Physician-Led RR-TB Treatment
The goal of the BringBPaL2Me Trial, a multi-principal investigator, multi-site, cluster randomized, non-inferiority trial is to compare nurse-led RR-TB treatment in primary care clinics to standard of care physician-led RR-TB…
- Trial name
- NCT05671718
- Testing
- Nurse-Led Treatment in Primary Care
- Where
- 5 sites in South Africa
- Volunteers
- 2,944 people
- Sponsor
- Johns Hopkins University
Pulmonary Tuberculosis
A PAN-USR TB Multi-Center Trial
Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide.
- Trial name
- NCT06905522
- Testing
- Bedaquiline (B), Sitafloxacin (S), Linezolid (L)
- Where
- 3 sites in China
- Volunteers
- 610 people
- Sponsor
- Shenzhen Third People's Hospital
Tuberculosis, Pulmonary
A Short Regimen for Rifampicin-resistant Isoniazid-susceptible TB
To assess outcome of treatment and safety among patients with rifampicin-resistant isoniazid-susceptible pulmonary tuberculosis treated with a novel regimen consisting of isoniazid, bedaquiline, and moxifloxacin throughout for 6…
- Trial name
- NCT06526039
- Testing
- a novel short regimen
- Volunteers
- 100 people
- Sponsor
- Taipei Medical University WanFang Hospital
Tuberculosis Infection, Latent
Shorter and Safer Treatment Regimens for Latent TB
Our study rationale is based on: 1. Tuberculosis Preventive Treatment (TPT) is given to healthy people and needs to be safe; 2. Tuberculosis Preventive Treatment (TPT) with shorter regimens are superior with respect to…
- Trial name
- SSTARLET (NCT06498414)
- Testing
- rifampin standard arm, rifampin double dose, levofloxacin and rifapentine
- Where
- 14 sites in Benin, Brazil and 3 more
- Volunteers
- 1,800 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Tuberculosis in HIV-infected Individuals, Drug Susceptible Pulmonary Tuberculosis
Short-Course Regimens for DS-PTB in AIDS Patients
This study adopts a multicenter, open-label, randomized controlled design, conducted across key designated AIDS diagnosis and treatment hospitals nationwide.
- Trial name
- NCT07608172
- Testing
- 2HPMZ/2HPM, 2HRZE/4HR
- Volunteers
- 148 people
- Sponsor
- Shanghai Public Health Clinical Center
Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis
Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB)
The INSPIRE-TB study is a pragmatic, multicentre, randomised, controlled, non-inferiority open-label trial to evaluate the efficacy and safety of seven 9-month oral regimens compared to a 9-month standard of care (SOC) regimen in…
- Conditions
- Multidrug Resistant Tuberculosis, Rifampicin Resistant Tuberculosis, Pre-XDR-TB
- Trial name
- INSPIRE-TB (NCT05081401)
- Testing
- Bdq(Lzd)+Lfx(Mfx)+Cfz(Cs)+Pto+E+H+Z, A1, A2a
- Where
- 5 sites in China
- Volunteers
- 1,050 people
- Sponsor
- Huashan Hospital
Healthy Adult Participants
An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants
This study is an open-label, fixed-sequence, two-period Phase 1 clinical trial in healthy adult Chinese participants with a total of 3 cohorts, 16-20 healthy adult Chinese participants are planned to be enrolled in each cohort.
- Trial name
- SIM0270-104 (NCT07357610)
- Testing
- SIM0270, itraconazole, Rifampin
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Tuberculosis, Tuberculosis, Pulmonary
Shortened Regimen for Drug-susceptible TB in Children
While drug-susceptible tuberculosis (TB) disease in children currently requires four to six months of treatment, most children may be able to be cured with a shorter treatment of more powerful drugs.
- Conditions
- Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis, Lymph Node, Mycobacterium Tuberculosis
- Trial name
- SMILE-TB (NCT06253715)
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 9 sites in India, Indonesia and 5 more
- Volunteers
- 860 people
- Sponsor
- Johns Hopkins University
Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterium Infection
Hypertonic Saline for MAC
The MAC-HS study is a testing whether hypertonic saline helps improve symptoms and clearance of mycobacteria in patients with M. avium complex lung infections.
- Trial name
- NCT04921943
- Testing
- Hypertonic saline, Azithromycin, Ethambutol
- Where
- 3 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Oregon Health and Science University
Colorectal Cancer
Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery
In this study, Investigator will compare mechanical bowel preparation with or without oral antibiotics in Left sided colorectal cancer patients undergoing elective surgery.
- Trial name
- NCT07429760
- Testing
- Rifampicin (R)
- Where
- Pakistan
- Volunteers
- 60 people
- Sponsor
- Shaukat Khanum Memorial Cancer Hospital & Research Centre
Staphylococcus Aureus Bacteremia
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
The goal of this open-label, pragmatic, randomized controlled clinical trial is to learn if patients with Staphylococcus aureus bacteremia (SAB) given the intervention of early dual intravenous (IV) antibiotic therapy will…
- Trial name
- SABEDTIO (NCT07148960)
- Testing
- Early Dual IV Antibiotic Therapy - MRSA, Early Dual IV Antibiotic Therapy - MSSA, Single Agent IV Antibiotic Therapy - MRSA
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- West Virginia University
Mycobacterium Avium Complex Pulmonary Disease
Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease
The goal of this clinical trial is to learn if adding contezolid works to shorten the length of treatment in mycobacterium avium pulmonary disease in adults. It will also learn about the safety of extended usage of contezolid.
- Trial name
- NCT07213765
- Testing
- Contezolid, Azithromycin, Ethambutol (E)
- Where
- 6 sites in China
- Volunteers
- 188 people
- Sponsor
- Bin Cao